Incyte’s skin disease drug meets main goal in two late-stage studies
By Thomson ReutersMar 17, 2025 | 6:37 AM
(Reuters) -Incyte said on Monday its experimental drug has met the main goal in two separate late-stage studies testing it in patients with an inflammatory skin condition called hidradenitis suppurativa.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Shailesh Kuber)
Comments